Please Wait
Applying Filters...
menu
    • menu
    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Sapanisertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Faeth Therapeutics' Phase 2 DICE Trial Reveals 34% Lower Disease
    Faeth Therapeutics' Phase 2 DICE Trial Reveals 34% Lower Disease

    19 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-19/esmo-2025-faeth-therapeutics-phase-2-dice-trial-shows-34-reduction-in-risk-of-disease-progression

    PHARMIWEB
    19 Oct 2025
    Share Share
    Faeth Therapeutics and GOG Foundation Launch Phase 2 Trial
    Faeth Therapeutics and GOG Foundation Launch Phase 2 Trial

    12 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250312383430/en

    BUSINESSWIRE
    12 Mar 2025
    Share Share
    Faeth Therapeutics to Present at Raymond James Biotech Private Company Showcase
    Faeth Therapeutics to Present at Raymond James Biotech Private Company Showcase

    17 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240717288408/en

    BUSINESSWIRE
    17 Jul 2024
    Share Share
    Calithera Receives FDA Fast Track Designation for Sapanisertib
    Calithera Receives FDA Fast Track Designation for Sapanisertib

    03 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/03/2526655/0/en/Calithera-Receives-FDA-Fast-Track-Designation-for-Sapanisertib-for-the-Treatment-of-NRF2-mutated-Squamous-Lung-Cancer.html

    GLOBENEWSWIRE
    03 Oct 2022
    Share Share
    Calithera Biosciences Reports Second Quarter 2022 Financial Results
    Calithera Biosciences Reports Second Quarter 2022 Financial Results

    15 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/15/2498526/32478/en/Calithera-Biosciences-Reports-Second-Quarter-2022-Financial-Results-and-Recent-Highlights.html

    GLOBENEWSWIRE
    15 Aug 2022
    Share Share
    Calithera Bio Shares Progress in Sapanisertib and Mivavotinib Clinical Programs
    Calithera Bio Shares Progress in Sapanisertib and Mivavotinib Clinical Programs

    13 Jul 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/07/13/2479319/32478/en/Calithera-Biosciences-Shares-Progress-in-Sapanisertib-and-Mivavotinib-Clinical-Programs-at-Upcoming-Lung-Cancer-and-Lymphoma-Conferences.html

    GLOBENEWSWIRE
    13 Jul 2022
    Share Share